Sandia Holdings’s Blueprint Medicines BPMC Stock Holding History

Sandia Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$6.42M	Sell	82,309 -13,043	-14%	-$907K	3.01%	14
2018 Q2	$6.05M	Sell	95,352 -14,300	-13%	-$1.14M	2.71%	15
2018 Q1	$10.1M	Sell	109,652 -25,933	-19%	-$2.24M	4.66%	10
2017 Q4	$10.2M	Sell	135,585 -36,237	-21%	-$2.55M	4.66%	7
2017 Q3	$12M	Sell	171,822 -131,819	-43%	-$7.04M	5.14%	7
2017 Q2	$15.4M	Sell	303,641 -188,700	-38%	-$8.01M	7.18%	5
2017 Q1	$19.7M	Sell	492,341 -208,650	-30%	-$7.47M	9.92%	2
2016 Q4	$19.7M	Buy	+700,991	New	+$21.1M	10.63%	1

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Sandia Holdings's BPMC Position: Q3 2018 in Review

Sandia Holdings reduced its Blueprint Medicines (BPMC) stake by 14% in Q3 2018, selling an estimated $907K and leaving 82,309 shares worth $6.42M. The position accounts for 3.01% of the portfolio, ranked #14.

Sandia Holdings first reported a position in BPMC in Q4 2016 and has held it in 8 quarters since. The position peaked at $19.7M in Q1 2017. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

Sandia Holdings held 82,309 shares of Blueprint Medicines worth $6.42M as of Q3 2018.
Sandia Holdings sold 13,043 Blueprint Medicines shares in Q3 2018, an estimated $907K.
Blueprint Medicines made up 3.01% of Sandia Holdings's portfolio in Q3 2018, its #14 holding.
Sandia Holdings first reported a position in Blueprint Medicines in Q4 2016 and has held it in 8 quarters since.
Sandia Holdings's Blueprint Medicines position peaked at $19.7M in Q1 2017.
188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on Sandia Holdings's 13F filing for Q3 2018, filed 13 Nov 2018.